Report blames gaming of patent system for high drug prices: Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.

Med City News, August 9, 2018
Alaric Dearment, quoting W. Nicholson Price II (Academic Fellow Alumnus)

[...] The report, “Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices,” was released last week by the nonprofit Initiative for Medicines, Access and Knowledge, also known as I-MAK. The report found that the 12 highest-grossing…

Read More

Katie Kraschel Named One of ABA’s Top 40 Young Lawyers

Solomon Center for Health Law and Policy at Yale Law School, August 9, 2018
Honoring Katie Kraschel (Student Fellow Alumna)

Katie Kraschel, Executive Director of the Solomon Center for Health Law and Policy,  has been named among the American Bar Association’s “Top 40 Young Lawyers” for 2018. The…

Read More

Penn State forms addiction legal resources team at Dickinson Law

Penn State News , July 30, 2018
Kristie Auman-Bauer, featuring Matthew Lawrence (Academic Fellow Alumnus)

From the article:  CARLISLE, Pa. — With the number of opioid overdose deaths continuing to rise in Pennsylvania, a group of Penn State Dickinson Law students and faculty are becoming advocates and providing resources for those who are affected by addictions. …

Read More

A Fear of Lawsuits Really Does Seem to Result in Extra Medical Tests

The New York Times, July 23, 2018
Margot Sanger-Katz, featuring Michael Frakes (Academic Fellow Alumnus)

From the article:  Mr. Gruber and Michael D. Frakes, a Duke economist and lawyer, looked at the health care system for active-duty members of the military. Under longstanding law, such patients get access to a government health care system but are barred from…

Read More

The Health 202: This mother’s tweet about drug prices went viral. Trump’s plans are unlikely to help

Washington Post, July 24, 2018
by Colby Itkowitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “It’s going to take a lot of time and there's a lot of hurdles in the way, but that’s not what you want to explain when you want to show how you’re lowering drug prices,” he told me. “Ultimately they are going…

Read More

Unpacking the bold — and the bluster — in Trump’s plan to bring down drug prices

STAT, July 23, 2018
by Erin Mershon, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: The administration says the proposal will save Medicare money, which could translate into lower premiums. It will also mean lower co-pays for any beneficiary who might need a new drug when it first comes onto the market, since those payments are…

Read More

The Trump administration finally has one good idea to lower drug prices

Vox, July 20, 2018
by Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Right now, in the above circumstances and when there isn’t an actual drug shortage, “we don’t have a good policy solution,” Scott Gottlieb, the FDA commissioner, told me Thursday in a brief phone interview.

Read More

Update: UK Ministers Quit Over Brexit

BBC, July 9, 2018
Interview featuring Rachel Sachs (Academic Fellow Alumna)

From the interview: We consider the implications for Brexit as two senior UK ministers resign. David Henig is UK director of the European Centre For International Political Economy. He explains why this could be just the start of a government crisis. President…

Read More

HHS forced to choose migrants over medicines

Politico, July 18, 2018
By Dan Diamond, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Echoing the pharma industry, Verma stressed that the state's request violated current law — the first time she's publicly cited a legal defense. “f you want to go forward with negotiating with…

Read More

What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

STAT, July 11, 2018
By Erin Mershon and Ike Swetlitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Pfizer, to back down on a series of price hikes.

Read More

The Health 202: ‘ACA’ removed from swaths of website, watchdog reports

Washington Post, July 12, 2018
By Colby Itkowitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: As The Post’s Damian Paletta also noted, the announcement was an example of Trump’s successful use of the presidential bully pulpit. “This is not an industry that compromises,” Rachel Sachs, an associate professor…

Read More

The News on Drug Prices? Nothing Good

The New York Times, July 17, 2018
By The Editorial Board, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “It takes away a substantial tool that a lot of states were hoping to use,” says Rachel Sachs, a law professor and drug policy expert at Washington University in St. Louis. It also points to a hypocrisy, she says. “They’re…

Read More

Pro-ACA group: Court pick Kavanaugh refused to uphold pre-existing condition ban

PolitiFact, July 18, 2018
By Jon Greenberg, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: For the makers of the ad, this is very simple. "Two judges upheld the Affordable Care Act and its patient protections, and he declined to uphold it," Demand Justice executive director Brian Fallon said. "He could…

Read More

Donald Trump’s phony war on high prescription drug prices, explained

Vox, July 13, 2018
By Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Pfizer ended up agreeing to postpone its price hikes for now. The president was happy to take credit for that news, even if all he had really won was a temporary delay. Certainly not a “massive” cut. “It’s…

Read More

Fox News pundit says Brett Kavanaugh is pro-Obamacare. Is he?

PolitiFact, July 11, 2018
By Jon Greenberg, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: In the 2011 case, Blumstein said Kavanaugh showed "a traditional norm of judicial restraint." Mark Hall at Wake Forest University echoed that point. He sees Kavanaugh’s opinions as focused on legal fundamentals. …

Read More

As Arkansas ushers in new Trump-era Medicaid rules, thousands fear losing benefits

Reuters, July 10, 2018
By Yasmeen Abutaleb, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: Days after the ruling, Kentucky Governor Matt Bevin cut dental and vision benefits for some 460,000 state Medicaid recipients, saying the benefits were dependent on implementation of the community engagement requirements. Without the new rules, “immediate…

Read More

Abortion row reignites as US Supreme Court justice retires

The Citizen, June 29, 2018
By AFP, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: Allison Hoffman, a law professor at the University of Pennsylvania, says many Supreme Court decisions that fell short of a full repeal of Row vs Wade have nevertheless eroded women’s rights. “If repealed,…

Read More

Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics

Duke-Margolis Center for Heath Policy, June 14, 2018
Webcast featuring Jonathan J. Darrow (Student Fellow Alumnus)

From the webcast: Convened by the Duke-Robert J. Margolis, MD, Center for Health Policy at Duke University and supported by a cooperative agreement with FDA, this public event will focus on the range of non-traditional pharmaceutical approaches being developed to…

Read More

CMS quit test of pricey cancer treatment amid concerns over industry role

Politico, July 9, 2018
By Sarah Karlin-Smith and David Pittman, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “Coming from an administration which has a stated goal of trying to reduce drug pricing, trying to reduce overall drug spending and health care spending … at every turn this administration has taken steps in the opposite direction and…

Read More

Viagra goes up AGAIN: Pfizer hikes the cost of 100 best-sellers a month after Trump said he'd persuaded Big Pharma to carry out 'massive' price drops

Daily Mail, July 2, 2018
By Mia De Graaf, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Economists are now calling on the Department of Health and Human Services to clarify what kind of measures they were planning on levying against companies that did not stick to the plan.  'July 1 is a very…

Read More